Terutroban

Terutroban
	File:Terutroban structure.svg
Systematic (IUPAC) name
	Sodium 3-((6R)-6-{[(4-chlorophenyl)sulfonyl]amido}-2-methyl-5,6,7,8-tetrahydronaphthalen-1-yl]propanoate
Clinical data
Routes of; administration	Oral
Legal status
Legal status	Investigational;
Pharmacokinetic data
Biological half-life	6-10 hours
Identifiers
ATC code	none
PubChem	CID 23674098
Chemical data
Formula	C20H21ClNNaO4S
Molar mass	429.892 g/mol[[Script error: No such module "String".]]
	Script error: No such module "collapsible list".

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Terutroban is an antiplatelet agent developed by Servier Laboratories. As of 2008^[update], it is tested for the secondary prevention of acute thrombotic complications in the Phase III clinical trial PERFORM.

Method of action

Terutroban is a selective antagonist of the thromboxane receptor. It blocks thromboxane induced platelet aggregation and vasoconstriction.

H. Spreitzer (January 29, 2007). "Neue Wirkstoffe - Terutroban". Österreichische Apothekerzeitung (in German) (3/2007): 116.
Sorbera, LA, Serradell, N, Bolos, J, Bayes, M (2006). "Terutroban sodium". Drugs of the Future. 31 (10): 867–873. doi:10.1358/dof.2006.031.10.1038241.

40px	This drug article relating to the blood and blood forming organs is a stub. You can help ssf by expanding it. v d e